Page 16 - Project Bioshield News Today

SciCheck Digest A businessman’s post on Instagram and Facebook wrongly claims that the U.S. government “changed the definition of pandemic” in 2004, suggesting that COVID-19 would not have qualified under the old definition. There’s no evidence for those claims — and COVID-19 is by all means a pandemic. How lethal is COVID-19? It’s difficult to know exactly how deadly COVID-19 is, but as the World Health Organization has written, studies estimate that the i...

Jul 19, 2021 While Japan is lagging far behind other countries in developing COVID-19 vaccines, the United States is already supplying its shots to the rest of the world. The gap reflects the differences between what the two nations have learned from past bioterrorism attacks and epidemics of emerging and re-emerging infectious diseases that occurred not only within the country but also elsewhere, and how they prepared for future risks and crises. The following comment is not taken fro...

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

The Jab, Star Wars, and the Bubble Net of Digital Gulags In the new world, it is not the big fish which eats the small fish, its the fast fish which eats the slow fish. -- Klaus Schwab by Paul Haeder / May 22nd, 2021 See, hear, speak no evil! And, we are the slow fish, the 80 percent: The world’s 85 richest individuals possess as much wealth as the 3.5 billion souls who compose the poorer half of the world’s population, or so it was announced in a report by Oxfam International. The assertio...

Soligenix, Inc.: Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Japan Patent Office has allowed the patent application titled "Systems and Methods for Producing Synthetic...

Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma News provided by Share this article Share this article PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced toda...

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results News provided by Share this article Share this article PRINCETON, N.J., May 17, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2021. ...

Broad Efficacy and Improved Safety Profile of HyBryte™ Presented at Society for Investigative Dermatology Virtual Meeting News provided by Share this article Share this article PRINCETON, N.J., May 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ellen Kim, MD, Medical Director, Dermatolog...

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...